Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of fruquintinib in metastatic colorectal cancer
ChiCTR2400093871Phase 4Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of fruquintinib in metastatic colorectal adenocarcinoma (mCRC) (5 cohorts), sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Total progression-free survival, Progression-free survival and 1 more. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
fruquintinib
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on ChiCTR2400093871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093871.